Study: Statins don't cause cancer

We know statins lower LDL, or "bad" cholesterol. We also know that they tend to lower HDL, or "good" cholesterol, too. And we suspect that it's possible for low LDL levels to boost the risk of cancer. So, do statins increase the risk of cancer? Well, no, according to a new metanalysis published in the Journal of the American College of Cardiology.

The study found that yes, statins lowered LDL and that patients with lower LDL did have a greater risk of cancer. But, their statistics showed, the statins weren't the culprit in that cancer risk. You see, the people in the studies who didn't take statins also had a higher risk of cancer if their LDL was lower. And that risk in both lower-LDL groups was roughly the same.

Still, cardiology experts said that the FDA and drugmakers should analyze their statin trial data for cancer incidence, because the possible link between very low LDL and cancer is worrisome--and therefore it might not be safe to use statins to push cholesterol to super-low levels. That could trade lower cardio risk for higher cancer risk.

--read the item at Pharmalot
--see the study in JACC
--check out an analysis from Heartwire

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.